GlassScriptPhysician profile
Eric Omar Then
NPI 1336677798
$2,332.75
in general payments reported to CMS, 2019-2025
10 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $96.92 · 2021: $24.11 · 2022: $1,274 · 2023: $479 · 2024: $318 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $911.34 | 2022-2023 | Creon, Mavyret |
| Boston Scientific Corporation | $462.07 | 2022-2025 | Axios, Exalt Model D, General - Biliary Devices |
| Gilead Sciences, INC. | $351.10 | 2022-2023 | |
| Novo Nordisk INC | $343.95 | 2020-2023 | Rybelsus, Ozempic |
| Conmed Corporation | $71.27 | 2024 | Conmed Biliary |
| Takeda Pharmaceuticals U.S.A., INC. | $56.73 | 2022-2023 | Gattex |
| Nestle Healthcare Nutrition INC. | $47.34 | 2021-2022 | |
| Redhill Biopharma INC. | $42.27 | 2022 | |
| Janssen Biotech, INC. | $29.43 | 2023 | Stelara, Simponi Aria, Remicade |
| Alcresta Therapeutics, INC. | $17.25 | 2023 | Relizorb |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Then listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.